Abdominal Imaging

, Volume 40, Issue 6, pp 1871–1886 | Cite as

Approach to risk stratification in testicular germ cell tumors: a primer for radiologists

  • Monica J. Wood
  • Sree Harsha Tirumani
  • Christopher Sweeney
  • Nikhil H. Ramaiya
  • Stephanie A. Howard
Pictorial Essay
First Online:

Abstract

Oncologists increasingly exploit differences in testicular germ cell tumors to deliver more personalized treatment. Imaging is essential in this process, aiding in the selection of risk-stratified management strategies. Consideration of relevant prognostic factors strengthens image interpretation, allowing for a more nuanced radiographic evaluation. This paper uses a clinically focused, stage-by-stage approach to delineate the risk factors for relapse and metastasis that radiologists should consider during staging, response assessment, and surveillance.

Keywords

Testicular germ cell tumors Testicular cancer imaging Risk stratification Prognosis 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

None.

References

  1. 1.
    Shanmugalingam T, Soultati A, Chowdhury S, Rudman S, Van Hemelrijck M (2013) Global incidence and outcome of testicular cancer. Clin Epidemiol 5:417–427. doi: 10.2147/clep.s34430 PubMedCentralPubMedGoogle Scholar
  2. 2.
    Znaor A, Lortet-Tieulent J, Jemal A, Bray F (2013) International variations and trends in testicular cancer incidence and mortality. Eur Urol . doi: 10.1016/j.eururo.2013.11.004 PubMedGoogle Scholar
  3. 3.
    Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi: 10.3322/caac.21208 PubMedCrossRefGoogle Scholar
  4. 4.
    Ulbright TM, Amin MB, Young RH (1999) Tumors of the testis, adnexa, spermatic cord and scrotum. In: Rosai J, Sobin LH (eds) Atlas of tumor pathology, fasc 25, ser 3. Washington, DC: Armed Forces Institute of Pathology, pp 1–290Google Scholar
  5. 5.
    Klepp O, Flodgren P, Maartman-Moe H, et al. (1990) Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol 1(4):281–288PubMedGoogle Scholar
  6. 6.
    Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ (2008) Medical treatment of advanced testicular cancer. J Am Med Assoc 299(6):672–684. doi: 10.1001/jama.299.6.672 CrossRefGoogle Scholar
  7. 7.
    Rifkin MD, Kurtz AB, Pasto ME, Goldberg BB (1985) Diagnostic capabilities of high-resolution scrotal ultrasonography: prospective evaluation. J Ultrasound Med 4(1):13–19PubMedGoogle Scholar
  8. 8.
    Schwerk WB, Schwerk WN, Rodeck G (1987) Testicular tumors: prospective analysis of real-time US patterns and abdominal staging. Radiology 164(2):369–374. doi: 10.1148/radiology.164.2.3299487 PubMedCrossRefGoogle Scholar
  9. 9.
    Dogra VS, Gottlieb RH, Oka M, Rubens DJ (2003) Sonography of the scrotum. Radiology 227(1):18–36. doi: 10.1148/radiol.2271001744 PubMedCrossRefGoogle Scholar
  10. 10.
    Carkaci S, Ozkan E, Lane D, Yang WT (2010) Scrotal sonography revisited. J Clin Ultrasound JCU 38(1):21–37. doi: 10.1002/jcu.20642 PubMedGoogle Scholar
  11. 11.
    Marth D, Scheidegger J, Studer UE (1990) Ultrasonography of testicular tumors. Urol Int 45(4):237–240PubMedCrossRefGoogle Scholar
  12. 12.
    Gross AJ, Heinzer H, Loy V, Dieckmann KP (1992) Unusual differential diagnosis of testis tumor: intrascrotal sarcoidosis. J Urol 147(4):1112–1114PubMedGoogle Scholar
  13. 13.
    Basekim CC, Kizilkaya E, Pekkafali Z, Baykal KV, Karsli AF (2000) Mumps epididymo-orchitis: sonography and color Doppler sonographic findings. Abdom Imaging 25(3):322–325PubMedCrossRefGoogle Scholar
  14. 14.
    Serra AD, Hricak H, Coakley FV, et al. (1998) Inconclusive clinical and ultrasound evaluation of the scrotum: impact of magnetic resonance imaging on patient management and cost. Urology 51(6):1018–1021PubMedCrossRefGoogle Scholar
  15. 15.
    Tsili AC, Argyropoulou MI, Giannakis D, Sofikitis N, Tsampoulas K (2010) MRI in the characterization and local staging of testicular neoplasms. AJR Am J Roentgenol 194(3):682–689. doi: 10.2214/ajr.09.3256 PubMedCrossRefGoogle Scholar
  16. 16.
    AJCC (2010) Ophthalmic Oncology Task Force. Sarcoma of the orbit. In: Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) AJCC cancer staging manual, 7th edn. New York: Springer, pp 469–478Google Scholar
  17. 17.
    Weiss RM, George NJR, O’Reilly PH (2001) Comprehensive urology. London: MosbyGoogle Scholar
  18. 18.
    Donohue JP, Zachary JM, Maynard BR (1982) Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 128(2):315–320PubMedGoogle Scholar
  19. 19.
    Motzer RJ, Agarwal N, Beard C, et al. (2012) Testicular cancer. J Natl Compr Cancer Netw JNCCN 10(4):502–535PubMedGoogle Scholar
  20. 20.
    See WA, Hoxie L (1993) Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. J Urol 150(3):874–878PubMedGoogle Scholar
  21. 21.
    Horan G, Rafique A, Robson J, Dixon AK, Williams MV (2007) CT of the chest can hinder the management of seminoma of the testis; it detects irrelevant abnormalities. Br J Cancer 96(6):882–885. doi: 10.1038/sj.bjc.6603657 PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    White PM, Adamson DJ, Howard GC, Wright AR (1999) Imaging of the thorax in the management of germ cell testicular tumours. Clin Radiol 54(4):207–211PubMedCrossRefGoogle Scholar
  23. 23.
    Tandstad T, Dahl O, Cohn-Cedermark G, et al. (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 27(13):2122–2128. doi: 10.1200/jco.2008.18.8953 PubMedCrossRefGoogle Scholar
  24. 24.
    Albers P, Siener R, Krege S, et al. (2008) Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26(18):2966–2972. doi: 10.1200/jco.2007.12.0899 PubMedCrossRefGoogle Scholar
  25. 25.
    Horwich A, Alsanjari N, A’Hern R, et al. (1992) Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 65(5):775–778PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    von der Maase H, Specht L, Jacobsen GK, et al. (1993) Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer (Oxf) 29(14):1931–1934Google Scholar
  27. 27.
    Germa-Lluch JR, Garcia del Muro X, Maroto P, et al. (2002) Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 42(6):553–562; discussion 562–553Google Scholar
  28. 28.
    Daugaard G, Petersen PM, Rorth M (2003) Surveillance in stage I testicular cancer. APMIS 111(1):76–83; discussion 83–75Google Scholar
  29. 29.
    Tyldesley S, Voduc D, McKenzie M, et al. (2006) Surveillance of stage I testicular seminoma: British Columbia Cancer Agency Experience 1992 to 2002. Urology 67(3):594–598. doi: 10.1016/j.urology.2005.09.050 PubMedCrossRefGoogle Scholar
  30. 30.
    Leung E, Warde P, Jewett M, et al. (2013) Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy. BJU Int 112(8):1088–1095. doi: 10.1111/bju.12330 PubMedCrossRefGoogle Scholar
  31. 31.
    Oliver RT, Mason MD, Mead GM, et al. (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366(9482):293–300. doi: 10.1016/s0140-6736(05)66984-x PubMedCrossRefGoogle Scholar
  32. 32.
    Albers P, Siener R, Kliesch S, et al. (2003) Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 21(8):1505–1512. doi: 10.1200/jco.2003.07.169 PubMedCrossRefGoogle Scholar
  33. 33.
    Williams SB, Kacker R, Winston D, et al. (2011) Predictors of positive retroperitoneal lymph nodes in patients with high risk testicular cancer. J Urol 186(6):2245–2248. doi: 10.1016/j.juro.2011.07.101 PubMedCrossRefGoogle Scholar
  34. 34.
    Krege S, Beyer J, Souchon R, et al. (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 53(3):478–496. doi: 10.1016/j.eururo.2007.12.024 PubMedCrossRefGoogle Scholar
  35. 35.
    Sweeney CJ, Hermans BP, Heilman DK, et al. (2000) Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma—predominant testis cancer. J Clin Oncol 18(2):358–362PubMedGoogle Scholar
  36. 36.
    Vergouwe Y, Steyerberg EW, Eijkemans MJ, Albers P, Habbema JD (2003) Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 21(22):4092–4099. doi: 10.1200/jco.2003.01.094 PubMedCrossRefGoogle Scholar
  37. 37.
    Stephenson AJ, Sheinfeld J (2005) Management of patients with low-stage nonseminomatous germ cell testicular cancer. Curr Treat Options Oncol 6(5):367–377PubMedCrossRefGoogle Scholar
  38. 38.
    Howard S, Gray K, Fennessey F, et al. (2014) Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. Am J Roentgenol 203:W415–W420CrossRefGoogle Scholar
  39. 39.
    Warde P, Specht L, Horwich A, et al. (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20(22):4448–4452PubMedCrossRefGoogle Scholar
  40. 40.
    Rustin GJ, Mead GM, Stenning SP, et al. (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197—the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 25(11):1310–1315. doi: 10.1200/jco.2006.08.4889 PubMedCrossRefGoogle Scholar
  41. 41.
    Chung PW, Bedard P (2011) Stage II seminomas and nonseminomas. Hematol Oncol Clin N Am 25(3):529–541, viii. doi: 10.1016/j.hoc.2011.03.009
  42. 42.
    Chung P, Warde P (2013) Contemporary management of stage I and II seminoma. Curr Urol Rep 14(5):525–533. doi: 10.1007/s11934-013-0365-2 PubMedCrossRefGoogle Scholar
  43. 43.
    Classen J, Schmidberger H, Meisner C, et al. (2003) Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21(6):1101–1106PubMedCrossRefGoogle Scholar
  44. 44.
    Chung PW, Gospodarowicz MK, Panzarella T, et al. (2004) Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 45(6):754–759; discussion 759–760. doi: 10.1016/j.eururo.2004.01.020
  45. 45.
    Thomas GM (1997) Over 20 years of progress in radiation oncology: seminoma. Semin Radiat Oncol 7(2):135–145. doi: 10.1053/srao00700135 PubMedCrossRefGoogle Scholar
  46. 46.
    Hilton S, Herr HW, Teitcher JB, Begg CB, Castellino RA (1997) CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 169(2):521–525. doi: 10.2214/ajr.169.2.9242768 PubMedCrossRefGoogle Scholar
  47. 47.
    Hudolin T, Kastelan Z, Knezevic N, et al. (2012) Correlation between retroperitoneal lymph node size and presence of metastases in nonseminomatous germ cell tumors. Int J Surg Pathol 20(1):15–18. doi: 10.1177/1066896911431452 PubMedCrossRefGoogle Scholar
  48. 48.
    Donohue JP, Thornhill JA, Foster RS, et al. (1995) The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol 153(1):85–89PubMedCrossRefGoogle Scholar
  49. 49.
    Stephenson AJ, Bosl GJ, Motzer RJ, et al. (2007) Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol 25(35):5597–5602. doi: 10.1200/jco.2007.12.0808 PubMedCrossRefGoogle Scholar
  50. 50.
    Williams SD, Stablein DM, Einhorn LH, et al. (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317(23):1433–1438. doi: 10.1056/nejm198712033172303 PubMedCrossRefGoogle Scholar
  51. 51.
    Sohaib SA, Koh DM, Barbachano Y, et al. (2009) Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol 64(4):362–367. doi: 10.1016/j.crad.2008.10.011 PubMedCrossRefGoogle Scholar
  52. 52.
    Hogeboom WR, Hoekstra HJ, Mooyaart EL, et al. (1991) The role of magnetic resonance imaging and computed tomography in the treatment evaluation of retroperitoneal lymph-node metastases of non-seminomatous testicular tumors. Eur J Radiol 13(1):31–36PubMedCrossRefGoogle Scholar
  53. 53.
    Harisinghani MG, Saksena M, Ross RW, et al. (2005) A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology 66(5):1066–1071. doi: 10.1016/j.urology.2005.05.049 PubMedCrossRefGoogle Scholar
  54. 54.
    Eiber M, Beer AJ, Holzapfel K, et al. (2010) Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol 45(1):15–23. doi: 10.1097/RLI.0b013e3181bbdc2f PubMedCrossRefGoogle Scholar
  55. 55.
    Huddart RA, O’Doherty MJ, Padhani A, et al. (2007) 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22—the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 25(21):3090–3095. doi: 10.1200/jco.2006.09.3831 PubMedCrossRefGoogle Scholar
  56. 56.
    de Wit M, Brenner W, Hartmann M, et al. (2008) [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol 19(9):1619–1623. doi: 10.1093/annonc/mdn170 PubMedCrossRefGoogle Scholar
  57. 57.
    Einhorn LH, Donohue J (1977) Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87(3):293–298PubMedCrossRefGoogle Scholar
  58. 58.
    International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15(2):594–603Google Scholar
  59. 59.
    Carver BS, Sheinfeld J (2005) Germ cell tumors of the testis. Ann Surg Oncol 12(11):871–880. doi: 10.1245/aso.2005.01.013 PubMedCrossRefGoogle Scholar
  60. 60.
    Bredael JJ, Vugrin D, Whitmore WF Jr (1982) Autopsy findings in 154 patients with germ cell tumors of the testis. Cancer 50(3):548–551PubMedCrossRefGoogle Scholar
  61. 61.
    Lorch A, Beyer J, Bascoul-Mollevi C, et al. (2010) Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28(33):4906–4911. doi: 10.1200/jco.2009.26.8128 PubMedCrossRefGoogle Scholar
  62. 62.
    Sohaib SA, Cook G, Koh DM (2011) Imaging studies for germ cell tumors. Hematol Oncol Clin N Am 25(3):487–502, vii. doi: 10.1016/j.hoc.2011.03.014
  63. 63.
    Wood A, Robson N, Tung K, Mead G (1996) Patterns of supradiaphragmatic metastases in testicular germ cell tumours. Clin Radiol 51(4):273–276PubMedCrossRefGoogle Scholar
  64. 64.
    Dalal PU, Sohaib SA, Huddart R (2006) Imaging of testicular germ cell tumours. Cancer Imaging 6:124–134. doi: 10.1102/1470-7330.2006.0020 PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.
    Brunereau L, Bruyere F, Linassier C, Baulieu JL (2012) The role of imaging in staging and monitoring testicular cancer. Diagn Interv Imaging 93(4):310–318. doi: 10.1016/j.diii.2012.01.014 PubMedCrossRefGoogle Scholar
  66. 66.
    Boyle HJ, Jouanneau E, Droz JP, Flechon A (2013) Management of brain metastases from germ cell tumors: a single center experience. Oncology 85(1):21–26. doi: 10.1159/000351812 PubMedCrossRefGoogle Scholar
  67. 67.
    Oechsle K, Bokemeyer C (2011) Treatment of brain metastases from germ cell tumors. Hematol Oncol Clin N Am 25(3):605–613, ix. doi: 10.1016/j.hoc.2011.03.012
  68. 68.
    Oechsle K, Bokemeyer C, Kollmannsberger C, et al. (2012) Bone metastases in germ cell tumor patients. J Cancer Res Clin Oncol 138(6):947–952. doi: 10.1007/s00432-012-1169-3 PubMedCrossRefGoogle Scholar
  69. 69.
    Hitchins RN, Philip PA, Wignall B, et al. (1988) Bone disease in testicular and extragonadal germ cell tumours. Br J Cancer 58(6):793–796PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Jamal-Hanjani M, Karpathakis A, Kwan A, et al. (2013) Bone metastases in germ cell tumours: lessons learnt from a large retrospective study. BJU Int 112(2):176–181. doi: 10.1111/bju.12218 PubMedCrossRefGoogle Scholar
  71. 71.
    Rajarubendra N, Bolton D, Lawrentschuk N (2010) Diagnosis of bone metastases in urological malignancies—an update. Urology 76(4):782–790. doi: 10.1016/j.urology.2009.12.050 PubMedCrossRefGoogle Scholar
  72. 72.
    Puc HS, Heelan R, Mazumdar M, et al. (1996) Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 14(2):454–460PubMedGoogle Scholar
  73. 73.
    Becherer A, De Santis M, Karanikas G, et al. (2005) FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 54(2):284–288. doi: 10.1016/j.ejrad.2004.07.012 PubMedCrossRefGoogle Scholar
  74. 74.
    Bachner M, Loriot Y, Gross-Goupil M, et al. (2012) 2-(1)(8)Fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 23(1):59–64. doi: 10.1093/annonc/mdr052 PubMedCrossRefGoogle Scholar
  75. 75.
    Daneshmand S, Albers P, Fossa SD, et al. (2012) Contemporary management of postchemotherapy testis cancer. Eur Urol 62(5):867–876. doi: 10.1016/j.eururo.2012.08.014 PubMedCrossRefGoogle Scholar
  76. 76.
    Beyer J, Albers P, Altena R, et al. (2013) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24(4):878–888. doi: 10.1093/annonc/mds579 PubMedCentralPubMedCrossRefGoogle Scholar
  77. 77.
    Fox EP, Weathers TD, Williams SD, et al. (1993) Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11(7):1294–1299PubMedGoogle Scholar
  78. 78.
    Steyerberg EW, Keizer HJ, Sleijfer DT, et al. (2000) Retroperitoneal metastases in testicular cancer: role of CT measurements of residual masses in decision making for resection after chemotherapy. Radiology 215(2):437–444. doi: 10.1148/radiology.215.2.r00ma02437 PubMedCrossRefGoogle Scholar
  79. 79.
    Oechsle K, Hartmann M, Brenner W, et al. (2008) [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol 26(36):5930–5935. doi: 10.1200/jco.2008.17.1157 PubMedCrossRefGoogle Scholar
  80. 80.
    Kollmannsberger C, Oechsle K, Dohmen BM, et al. (2002) Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 94(9):2353–2362. doi: 10.1002/cncr.10494 PubMedCrossRefGoogle Scholar
  81. 81.
    Stephens AW, Gonin R, Hutchins GD, Einhorn LH (1996) Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 14(5):1637–1641PubMedGoogle Scholar
  82. 82.
    Sugawara Y, Zasadny KR, Grossman HB, et al. (1999) Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology 211(1):249–256. doi: 10.1148/radiology.211.1.r99ap16249 PubMedCrossRefGoogle Scholar
  83. 83.
    Pfannenberg AC, Oechsle K, Bokemeyer C, et al. (2004) The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors—prospects for management. World J Urol 22(2):132–139. doi: 10.1007/s00345-003-0392-6 PubMedCrossRefGoogle Scholar
  84. 84.
    Krege S, Beyer J, Souchon R, et al. (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 53(3):497–513. doi: 10.1016/j.eururo.2007.12.025 PubMedCrossRefGoogle Scholar
  85. 85.
    Oto A, Yacoub JH, Casalino DD, et al. (2012) ACR Appropriateness Criteria® staging of testicular malignancy. Am Coll Radiol. https://acsearch.acr.org/docs/69375/Narrative/. Accessed November 12, 2014
  86. 86.
    Petralia G, Thoeny HC (2010) DW-MRI of the urogenital tract: applications in oncology. Cancer Imaging 10(Spec no A):S112–123. doi: 10.1102/1470-7330.2010.9030
  87. 87.
    Gilbert DC, Chandler I, McIntyre A, et al. (2009) Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. J Pathol 217(1):94–102. doi: 10.1002/path.2436 PubMedCrossRefGoogle Scholar
  88. 88.
    Mayer F, Gillis AJ, Dinjens W, et al. (2002) Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 62(10):2758–2760PubMedGoogle Scholar
  89. 89.
    Velasco A, Corvalan A, Wistuba II, et al. (2008) Mismatch repair expression in testicular cancer predicts recurrence and survival. Int J Cancer 122(8):1774–1777. doi: 10.1002/ijc.23291 PubMedCrossRefGoogle Scholar
  90. 90.
    Honecker F, Wermann H, Mayer F, et al. (2009) Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 27(13):2129–2136. doi: 10.1200/jco.2008.18.8623 PubMedCrossRefGoogle Scholar
  91. 91.
    Ruf CG, Linbecker M, Port M, et al. (2012) Predicting metastasized seminoma using gene expression. BJU Int 110(2 Pt 2):E14–E20. doi: 10.1111/j.1464-410X.2011.10778.x PubMedCrossRefGoogle Scholar
  92. 92.
    Korkola JE, Houldsworth J, Feldman DR, et al. (2009) Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J Clin Oncol 27(31):5240–5247. doi: 10.1200/jco.2008.20.0386 PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Monica J. Wood
    • 1
  • Sree Harsha Tirumani
    • 2
    • 3
  • Christopher Sweeney
    • 4
  • Nikhil H. Ramaiya
    • 2
    • 3
  • Stephanie A. Howard
    • 2
    • 3
  1. 1.Harvard Medical SchoolBostonUSA
  2. 2.Department of Imaging, Dana-Farber Cancer InstituteHarvard Medical SchoolBostonUSA
  3. 3.Department of Radiology, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  4. 4.Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations